Topics

Bio-Thera Reports Positive Results from Phase III Trial of Avastin Biosimilar

23:11 EST 3 Feb 2020 | ChinaBio Today

Bio-Thera Solutions of Guangzhou reported positive top-line results from a Phase III clinical trial of its Avastin biosimilar. The trial compared the overall response rate (ORR) of BAT1706 to Avastin as a first-line treatment for non-squamous non-small cell lung cancer. The company plans to file for approval of the Avastin biosimilar this year in China, the US and the EU. One year ago, Bio-Thera out-licensed developing country rights for BAT1706 to India's Cipla Pharma. Bio-Thera is already marketing a Humira® biosimilar for auto-immune conditions in China. More details....

Stock Symbol: (BSE: 500087)

Share this with colleagues:

Original Article: Bio-Thera Reports Positive Results from Phase III Trial of Avastin Biosimilar

NEXT ARTICLE

More From BioPortfolio on "Bio-Thera Reports Positive Results from Phase III Trial of Avastin Biosimilar"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...